Johnson & Johnson's LifeScan unit, WellDoc to advance mobile solutions for type 2 diabetes

Johnson & Johnson's LifeScan unit and digital health technology company WellDoc announced a collaboration to advance mobile solutions for patients with type 2 diabetes with real time data and information to improve their health outcomes. Val Asbury, LifeScan's worldwide president, said WellDoc's "innovative" diabetes management platform "has been shown to improve health outcomes," adding "by working together, we look forward to advancing new solutions."

Under the deal, of which financial terms were not disclosed, the companies will work to integrate LifeScan's OneTouch Verio Flex blood glucose monitoring system and OneTouch Reveal mobile app with WellDoc's BlueStar diabetes management platform and mobile app. The companies noted that the BlueStar platform is the "first" mobile prescription therapy FDA approved for type 2 diabetes.

LifeScan indicated that its OneTouch Verio Flex features ColorSure technology, which is "a simple, accurate and easy-to-use metre that takes the guesswork out of understanding blood sugar test results for people with diabetes." LifeScan added "the integration would provide patients additional smart monitoring tools and real-time motivational, behavioural and educational coaching."

To read more Top Story articles, click here.